Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Interest & Investment Income (2018 - 2025)

10x Genomics' Interest & Investment Income history spans 8 years, with the latest figure at $6.9 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 52.88% year-over-year to $6.9 million; the TTM value through Dec 2025 reached $20.0 million, up 5.91%, while the annual FY2025 figure was $20.0 million, 5.91% up from the prior year.
  • Interest & Investment Income for Q4 2025 was $6.9 million at 10x Genomics, up from $5.2 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $6.9 million in Q4 2025 and bottomed at $49000.0 in Q3 2021.
  • The 5-year median for Interest & Investment Income is $4.0 million (2023), against an average of $3.1 million.
  • The largest annual shift saw Interest & Investment Income plummeted 96.21% in 2021 before it surged 5644.9% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $49000.0 in 2021, then soared by 5644.9% to $2.8 million in 2022, then skyrocketed by 63.98% to $4.6 million in 2023, then dropped by 2.34% to $4.5 million in 2024, then surged by 52.88% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Interest & Investment Income are $6.9 million (Q4 2025), $5.2 million (Q3 2025), and $4.3 million (Q2 2025).